INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease that is now regarded as an epidemic in some countries (Lovic et al., 2019; Olokoba et al., 2012; Unnikrishnan et al., 2017). Insulin resistance is the strongest predictor of developing T2DM (Bunt et al., 2007), thus, targeting insulin resistance can help prevent the development of T2DM (Fujimoto, 2000).

Dietary protein and, in particular, branched-chain amino acids (BCAAs; leucine, valine, isoleucine) stimulate muscle protein synthesis and regulate body weight and glucose homeostasis (Lynch & Adams, 2014). However, increased circulating levels of BCAAs are present in insulin-resistant
states like obesity and T2DM, and BCAA levels are predictive of future insulin resistance (Andersson-Hall et al., 2018; Lackey et al., 2013; Lian et al., 2015; Mccormack et al., 2013; Newgard et al., 2009; Wang et al., 2011). Furthermore, circulating levels of branched-chain α-keto-acids (BCKAs, metabolites of BCAAs) are elevated in insulin-resistant individuals (Adams, 2011; Giesbertz et al., 2015; Mccormack et al., 2013; Newgard et al., 2009). These observations raised the question of whether increased levels of BCAAs and BCKAs cause insulin resistance, or ARE symptoms of insulin resistance. α-ketoisocaproic acid (KIC, the ketoacid of leucine) suppresses insulin-stimulated glucose transport in L6 myotubes (Moghei et al., 2016). This effect is attenuated when branched-chain aminotransferase 2 (BCAT2), the enzyme that catalyzes the reversible conversion of leucine into KIC, is depleted. In addition, skeletal muscle mRNA levels of BCAT2 and of the E1β subunit of branched-chain α-ketoacid dehydrogenase (BCKD), the enzyme complex that catalyzes the irreversible oxidative decarboxylation of branched-chain α-ketoacids, are reduced in skeletal muscle of T2DM patients (Hernández-Alvarez et al., 2017). In liver of type 2 diabetic rats (Kuzuya et al., 2008) and adipose tissue of db/db mice (Lackey et al., 2013), protein levels of BCKD subunits are decreased. In addition, BCKD activity is downregulated in type 2 diabetic mice liver, adipose tissue, and skeletal muscle (Lian et al., 2015). These data suggest a role for muscle, liver, and adipose tissue catabolism of BCAA in the development of insulin resistance. It remains to be seen if reduced BCKD expression is causative.

Pro-inflammatory factors too are implicated in the development of insulin resistance (Shoelson et al., 2006). Tumor necrosis factor-α (TNF-α) (Feinstein et al., 1993; Hotamisligil et al., 1993), IL-6 (Kim et al., 2009), and homocysteine (Li et al., 2008; Wang et al., 2000, 2002) reduce insulin signaling.

Skeletal muscle is the main site of insulin regulation of glucose metabolism (Thiebaud et al., 1982). We previously demonstrated a negative effect of KIC on insulin-stimulated glucose transport in myotubes (Moghei et al., 2016). Here, our objective was to examine whether inflammatory factors would modulate the effect of KIC and if such modulation would depend on cellular level of BCAT2. We also asked whether manipulation of BCKD level would affect insulin-stimulated glucose uptake. We showed that whereas KIC suppressed insulin-stimulated glucose transport in myotubes, this was not modified by co-incubation with pro-inflammatory factors. The effect of KIC or pro-inflammatory factors was attenuated when BCAT2 was depleted. We also demonstrated a significant reduction in insulin-stimulated glucose transport in cells depleted of BCKD, especially in myotubes incubated with KIC, consistent with the assertion that defects in muscle BCAA catabolism is causative for insulin resistance.

## 2 MATERIALS AND METHODS

### 2.1 Reagents

Alpha modification of Eagle’s medium (AMEM), phosphate-buffered saline (PBS), trypsin, and antibiotic–antimycotic preparations were purchased from Wisent (St Bruno, Quebec, Canada). Fetal bovine serum (FBS), horse serum (HS), Lipofectamine RNAiMAX, and Opti-MEM 1X Reduced Serum Medium were purchased from Thermo Fisher Canada (Burlington, Ontario Canada). Amino acid-free RPMI 1640 medium was purchased from US Biologicals (Salem MA). Sodium 4-methyl-2-oxovalerate (sodium salt of KIC), 2-deoxyglucose, protease and phosphate inhibitor cocktails, anti-BCAT2 and anti-gamma tubulin antibodies, siRNA oligonucleotides, amino acid standard, o-Phthalaldehyde, interleukin-6, and homocysteine were purchased from Sigma Aldrich (Oakville, Ontario, Canada). Phospho (ph) ribosomal protein S6 kinase 1 (S6K1) (T389), ph-ribosomal protein S6 (S6) (S235/236), ph-Akt (S473), ph-SAPK/JNK (T183/Y185), ph-glycogen synthase (S641), BCKDH-E1α, horseradish peroxidase (HRP)-conjugated anti-rabbit and anti-mouse secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA). [3H]-2-deoxyglucose was purchased from Perkin Elmer (Markham, Ontario, Canada) while chemiluminescence substrate was from Millipore (Etobicoke, Ontario, Canada). TNF-α was purchased from Shenandoah Biotechnology (Warwick, PA).

### 2.2 Cell Culture

L6 rat skeletal muscle myoblasts were purchased from American Type Culture Collection. Cells were cultured in 10-cm plates with growth medium (GM: AMEM supplemented with 10% FBS and 1% antibiotic-antimycotic preparations) as described before (Moghei et al., 2016). Cells were seeded (2 × 10^5 cells/well) in six-well plates for western blot experiments or (10^5 cells/well) in 12-well plates for glucose transport experiments. They were allowed to proliferate for 48 hr or until they became 90–100% confluent. They were then shifted into differentiation medium (DM: AMEM, 2% HS, 1% antibiotic–antimycotic preparations) and replenished with fresh DM every 48 hr. Myotubes were used on d 5 or d 6 of differentiation.

### 2.3 siRNA gene silencing

On d 3 of differentiation, cells were transfected with 50 nM of BCAT2 siRNA oligonucleotides (sense 5′-CUAUGUGCGCGCCGGUGCUU, anti-sense 5′-AAGC...
ACCGGCCGCACAG), or 50 nM of scrambled siRNA oligonucleotides using Lipofectamine RNAiMAX reagent according to the manufacturer's instructions. Twenty-four h after transfection, DM that contained pro-inflammatory factors (homocysteine [50 μM], TNF-α [10 ng/ml] and IL-6 [10 ng/ml]) was added to each well (1 ml per well for six well plates; 0.5 ml per well for two well plates) for 48 hr to produce a chronic inflammatory response (Aguiirre et al., 2000). We used these reagents at indicated concentrations because homocysteine promotes the activation of inflammatory pathways both in vitro and in vivo (Wang et al., 2000, 2002) and hyperhomocysteinemia ranges between ~15 and 50 μM in humans (Lipton et al., 1997). TNF-α activates inflammatory responses at 0–10 ng/ml concentration range (Bhatnagar et al., 2010; Ciaraldi et al., 1997), while IL-6 induces the production of pro-inflammatory cytokines at 10 ng/ml (Romano et al., 1997). Myotubes were then starved of amino acids for 3 hr and then supplemented with or without KIC for 30 min. Incubation then continued with or without insulin for another 20 min. Cells were afterward used to assay glucose transport or were harvested for western blotting. Where indicated, cells were transfected with siRNA oligonucleotides designed against E1α subunit of BCKD (sense 5′-CAGAUCGUAGAUCUG, anti-sense 5′-AGUAACAGACACGAUCUG) as described above. Two days post transfection, and after 3 hr starvation in amino acid-free medium, myotubes were supplemented with or without KIC for 30 min. They were then treated with insulin and afterward used to assay glucose transport or were harvested and processed for western blotting.

2.4 Glucose transport

Following treatments, myotubes were washed 2x in PBS, then harvested with 10% trichloroacetic acid. Lysates were centrifuged at 2.3 g for 15 min. Supernatant containing free amino acids were neutralized in a 1:2:1:8 ratio (sample: potassium phosphate buffer: 0.1 N hydrochloric acid: HPLC grade water, respectively). Neutralized samples were precolumn derivatized with a 1:1 ratio of sample to o-Phthalaldehyde (29.28 mM). They were then injected into a YMC-Triart C18 column (C18, 1.9 μm, 75 × 3.0 mm; YMC America, Allentown, PA, USA) fitted onto an ultra-high-pressure liquid chromatography (UHPLC) system (Nexera X2, Shimadzu, Kyoto, Japan) that was connected to a fluorescence detector (Shimadzu, Kyoto, Japan; excitation: 340 nm; emission: 455 nm). Amino acids were eluted with a gradient solution derived from 20 mM potassium phosphate buffer (6.5 pH) mobile phase (mobile phase A) and a solution made from 45% acetonitrile, 40% methanol and 15% HPLC grade water (mobile phase B) at a flow rate of 0.8 ml/min. We used a gradient of 5%–100% of mobile phase B over 21 min. Amino acid concentrations were calculated using amino acid standard curves and were normalized to total protein.

2.5 Amino acid concentrations

Following treatments, myotubes were washed 2x in PBS, then harvested with 10% trichloroacetic acid. Lysates were centrifuged at 2.3 g for 15 min. Supernatant containing free amino acids were neutralized in a 1:2:1:8 ratio (sample: potassium phosphate buffer: 0.1 N hydrochloric acid: HPLC grade water, respectively). Neutralized samples were precolumn derivatized with a 1:1 ratio of sample to o-Phthalaldehyde (29.28 mM). They were then injected into a YMC-Triart C18 column (C18, 1.9 μm, 75 × 3.0 mm; YMC America, Allentown, PA, USA) fitted onto an ultra-high-pressure liquid chromatography (UHPLC) system (Nexera X2, Shimadzu, Kyoto, Japan) that was connected to a fluorescence detector (Shimadzu, Kyoto, Japan; excitation: 340 nm; emission: 455 nm). Amino acids were eluted with a gradient solution derived from 20 mM potassium phosphate buffer (6.5 pH) mobile phase (mobile phase A) and a solution made from 45% acetonitrile, 40% methanol and 15% HPLC grade water (mobile phase B) at a flow rate of 0.8 ml/min. We used a gradient of 5%–100% of mobile phase B over 21 min. Amino acid concentrations were calculated using amino acid standard curves and were normalized to total protein.

2.6 Western blot analysis

Following treatments, myotubes were washed 2x in PBS, then harvested with 10% trichloroacetic acid. Lysates were centrifuged at 2.3 g for 15 min. Supernatant containing free amino acids were neutralized in a 1:2:1:8 ratio (sample: potassium phosphate buffer: 0.1 N hydrochloric acid: HPLC grade water, respectively). Neutralized samples were precolumn derivatized with a 1:1 ratio of sample to o-Phthalaldehyde (29.28 mM). They were then injected into a YMC-Triart C18 column (C18, 1.9 μm, 75 × 3.0 mm; YMC America, Allentown, PA, USA) fitted onto an ultra-high-pressure liquid chromatography (UHPLC) system (Nexera X2, Shimadzu, Kyoto, Japan) that was connected to a fluorescence detector (Shimadzu, Kyoto, Japan; excitation: 340 nm; emission: 455 nm). Amino acids were eluted with a gradient solution derived from 20 mM potassium phosphate buffer (6.5 pH) mobile phase (mobile phase A) and a solution made from 45% acetonitrile, 40% methanol and 15% HPLC grade water (mobile phase B) at a flow rate of 0.8 ml/min. We used a gradient of 5%–100% of mobile phase B over 21 min. Amino acid concentrations were calculated using amino acid standard curves and were normalized to total protein.

2.7 Data presentation and statistical analysis

Glucose transport data are presented as pmol of 2-deoxyglucose per μg protein. Proteins for western blots were adjusted for loading using γ-tubulin values. Statistical analyses were performed using GraphPad Prism 7 software. Data are presented as mean ± SEM. One-way analysis of variance (ANOVA) was used and Tukey’s post-hoc tests were done to measure statistically significant differences among means. Significance was determined as p < 0.05.
3 | RESULTS

3.1 | Effect of inflammation and KIC on insulin-stimulated glucose transport

Homocysteine at up to 500 μM had no effect on insulin-stimulated glucose transport (Figure 1a), but a combination of inflammatory factors, including homocysteine, IL-6, and TNF-α (5 ng/ml) suppressed insulin-stimulated glucose transport ($p < 0.05$, Figure 1b). KIC significantly reduced insulin-stimulated glucose transport ($p < 0.05$, Figure 1b); co-incubation with pro-inflammatory factors did not have any further effect (Figure 1b).

3.2 | BCAT2 depletion abolished the effect of KIC and inflammatory factors on insulin-stimulated glucose transport

We previously showed that BCAT2 depletion abolished the effects of KIC on glucose transport (Moghei et al., 2016). We examined if this held true in an inflammatory environment. Consistent with our previous report, in BCAT2-depleted myotubes (Figure 2b, Figure S1a), suppression of insulin-stimulated glucose transport by the inflammatory factors was attenuated (Figure 2b). The presence of inflammation was confirmed with a significant increase in JNK phosphorylation (Figure 2c, Figure S1b), a marker of inflammation (Nieto-Vazquez et al., 2008). This suggests that even in the context of inflammation, KIC was converted back into leucine to suppress insulin-stimulated glucose transport. This is consistent with the observation that in myotubes with normal level of BCAT2, leucine intracellular concentrations, but not the concentration of valine, isoleucine, or glutamate tended to increase (~30%) in KIC-treated cells (Figure 3a–d).

3.3 | In inflammation, KIC does not affect glycogen synthase, Akt, S6K1, or S6 phosphorylation

There were no significant treatment effects on glycogen synthase phosphorylation (Figure 4a, Figure S2a). We measured the effect of KIC and inflammatory factors on Akt phosphorylation, as Akt is important for the translocation of GLUT4, an insulin-stimulated glucose transporter, from intracellular vesicles to the plasma membrane (Beg et al., 2017). Insulin significantly increased the phosphorylation (activation) of Akt in the SCR condition but there was no significant effect of KIC or inflammatory factors or BCAT2 depletion on this measure (Figure 4b, Figure S2b). Because S6K1 can catalyze the inhibitory serine phosphorylation of insulin receptor substrate-1 (IRS-1) and thereby induce insulin resistance (Gual et al., 2005; Moghei et al., 2016), we examined the phosphorylation of this kinase. Although insulin increased the phosphorylation of S6K1 (Figure 4c, Figure S2a) and tended to increase the phosphorylation of its substrate (ribosomal protein S6, Figure 4d, Figure S2b), neither KIC nor the inflammatory factors nor BCAT2 depletion affected these measures.

**FIGURE 1** Effect of KIC and inflammatory factors on insulin-stimulated glucose transport. L6 myoblasts were cultured in differentiation medium (DM) for 4 days. (a) On d 4 of differentiation, cells were incubated in DM containing varying concentrations of homocysteine (10–500 μM) for 24 hr. Incubation then continued in DM with homocysteine that was also supplemented with or without 100 nM insulin for 20 min, after which glucose transport assays were performed. (b) On d 4 of differentiation, cells were incubated with homocysteine (50 μM), IL-6 (10 ng/ml), and TNF-α (5 or 10 ng/ml) for 48 hr. Incubation then continued in the medium with pro-inflammatory factors that was also supplemented without (−KIC) or with 200 μM KIC (+KIC) for 30 min. After, cells were incubated with or without 100 nM insulin for 20 min followed by glucose transport assay. Glucose transport is expressed as picomole of 2-deoxyglucose transported into the cell/μg protein, and normalized to the no insulin (-insulin) group. Data are mean ± SEM; n = 3–4 independent experiments (in which cells from different passages and/or different batches of cells were used in the independent experiments), with three technical replicates per experiment (number of wells per treatment condition per experiment); *$p < 0.05$ versus insulin group in the -KIC condition.
Effect of BCKD depletion and KIC supplementation on insulin-stimulated glucose transport and insulin signaling

Whether reduced BCKD level causes insulin resistance has not been tested before. Depletion of BCKD-E1α (Figure 5a, Figure S3a) suppressed insulin-stimulated glucose transport by ~38% (p < 0.05, Figure 5b). Addition of KIC to the incubation medium further suppressed glucose transport (a ~ 42% decrease compared to the effect BCKD depletion alone, p < 0.05, Figure 5c). BCKD depletion and/or KIC supplementation did not have a significant effect on insulin-stimulated phosphorylation of Akt (Figure 5d, Figure S3b). KIC increased insulin-stimulated phosphorylation of S6K1, but not of S6, in BCKD-depleted cells (p < 0.001, Figure 5e,f, Figure S3c).

DISCUSSION

While previous studies show a link between elevated levels of BCAA and their metabolites on insulin resistance, an important question has been to ascertain whether increased circulating levels of BCAA/BCAA metabolites cause insulin resistance, or merely reflect insulin resistance. To answer this question, it is critical to study the effects of these amino acids and their metabolites in conditions that mimic insulin resistance. Here, we have demonstrated that (a) incubation of myotubes in KIC, or in a combination inflammatory factors suppressed insulin-stimulated glucose uptake; (b) addition of the inflammatory factors, alone or combined with KIC, on insulin-stimulated glucose transport was abrogated in myotubes depleted of BCAT2; (d) myotubes...
depleted of a critical subunit of BCKD had impaired insulin-stimulated glucose transport, especially when the cells were also incubated in KIC. Collectively, these data point to a critical role for muscle BCAA catabolism in the regulation of muscle glucose transport and, by implication, regulation of whole-body glucose metabolism.

Many correlational analysis (Felig et al., 1969; Giesbertz et al., 2015; McCormack et al., 2013; Perg et al., 2014; Wang et al., 2011) and mechanistic (Lackey et al., 2013; Newgard, 2012; Newgard et al., 2009) studies show a positive relationship between increased levels of circulating BCAA and BCAA metabolite, and insulin resistance. We and others have shown that BCAA (especially leucine) (Baum et al., 2005; Moghei et al., 2016; Tremblay & Marette, 2001) and metabolites of BCAA (Jang et al., 2016; Moghei et al., 2016) can induce insulin resistance of glucose transport in skeletal muscle/muscle cells. These pieces of evidence suggest that irrespective of the reasons behind the elevation in circulating BCAA may arise due to increased consumption and/or intestinal absorption and release of the amino acids into systemic circulation. Reduced BCAA consumption improves insulin sensitivity (Cummings et al., 2018; White et al., 2016). The increase in circulating BCAA/BCAA metabolites may also be due to impaired utilization, for example, due to reduced protein synthesis and/or increased proteolysis. Consistent with this, skeletal muscle (ViM & Garlick, 1975) and whole-body protein synthesis (Pereira et al., 2008) are reduced in insulin resistance and in type 2 diabetic individuals. Another possibility is impaired catabolism of these amino acids. In line with this, mRNA levels of the E1β subunit of BCKD are reduced in skeletal muscle of T2DM patients (Hernández-Alvarez et al., 2017). Also, BCKD activity is downregulated in skeletal muscle, liver and adipose tissue of type 2 diabetic mice (Lian et al., 2015). Interestingly, although mice lacking BCAT2 have elevated BCAA levels, they did not manifest insulin resistance (She et al., 2007). Inhibition of BCKD kinase (BDK), the enzyme that phosphorylates and inhibits BCKD, leads to reduced levels of BCAA and improved whole-body insulin sensitivity (White et al., 2018; Zhou et al., 2019). Here, we demonstrated that depletion of E1α subunit of BCKD impaired insulin-stimulated glucose transport.
uptake, which worsened in the presence of KIC. Together, these findings indicate that not only can metabolites of BCAA cause insulin resistance, reduced levels/activity of the enzymes involved in the catabolism of these amino acids too may be causative.

Insulin resistance in skeletal muscle is a main causative abnormality in the development of type 2 diabetes (DeFronzo & Tripathy, 2009). Although BCAT2 activity is high in muscle (Brosnan & Brosnan, 2006; Suryawan et al., 1998), it is generally thought that catabolism of BCAA beyond the formation of BCKA occurs predominantly in liver and adipose tissue (Harper et al., 1984; Herman et al., 2010), but with little activity in skeletal muscle (Harper et al., 1984). Nevertheless, increased muscle intracellular levels of KIC, isovaleric CoA, and of other BCAA metabolites are seen in insulin resistance (Giesbertz et al., 2015; Lynch & Adams, 2014; Newgard et al., 2009; Perng et al., 2014). In addition, mice with muscle-specific deletion of BDK have 60% and 40% reductions in muscle BCAA and plasma BCAA levels, respectively (Ishikawa et al., 2016). Furthermore, 3-hydroxyisobutyrate (3-HIB), a catabolic intermediate of the BCAA valine that is released from muscle, promotes insulin resistance by stimulating muscle uptake and accumulation of fatty acids (Jang et al., 2016). Our data showing that depletion of

FIGURE 4 Effect of KIC, inflammation, and BCAT2 depletion on glycogen synthase, Akt, S6K1, and S6 phosphorylation. Cells were transfected with control (SCR) or BCAT2 siRNA oligonucleotides as described in Figure 2. Twenty-four hour post transfection, myotubes were incubated in DM that contained TNF-α (10 ng/ml), IL-6 (10 ng/ml), and homocysteine (50 μM) for 48 hr. Cells were then treated with KIC and insulin as described in Figure 2. They were harvested and proteins immunoblotted against (a) ph-Glycogen synthaseSer641, (b) ph-AktSer473, (c) ph-S6K1Thr389, and (d) ph-S6Ser235/236. (a–d) Mean ± SEM; n = 3 independent experiments with three technical replicates per experiment; ##p < 0.01 versus no insulin in SCR condition.
E1α subunit of BCKD in myotubes impaired insulin-stimulated glucose transport and insulin signaling. On d 4 of differentiation, cells were transfected with control (SCR) or BCKD siRNA oligonucleotides. Forty-eight hours post transfection, myotubes were starved for 3 hr in serum- and amino acid-free RPMI medium. Cells were then supplemented without (−KIC) or with 200 μM KIC (+KIC) for 30 min. After, cells were incubated with (+insulin) or without (−insulin) insulin (100 nM) for 20 min. They were then harvested or used for glucose transport assay. Proteins in lysates were immunoblotted against (a) BCKD, (b) ph-Akt, (c) ph-S6K1, (d) ph-S6, (e) ph-Akt, (f) ph-S6, (g) IRS-1, and (h) BCKD. (a–f) Glucose transport, expressed as picomole of 2-deoxyglucose transported into the cell/μg protein and normalized to the SCR, no insulin group (−insulin). Data for BCKD, ph-Akt, and ph-S6 were normalized to no insulin in SCR condition, while for S6K1 data were normalized to the insulin group in SCR condition due to a lack of signal in the no insulin in SCR condition. (a–f) Mean ± SEM; n = 4 independent experiments with three technical replicates per experiment; $p < 0.05$, versus SCR; $\#p < 0.05$, $\#\#p < 0.01$ versus no insulin in SCR condition; $*p < 0.05$, $**p < 0.01$, $***p < 0.001$ versus insulin in SCR condition; $++p < 0.01$, $+++p < 0.001$ versus insulin in BCKD condition.
as endurance exercise (Lee et al., 2018; Wagenmakers et al., 1989), likely do so via increased BCKD level/BCAA catabolism (Shimomura et al., 2004; Shimomuras et al., 2006; Wagenmakers et al., 1989).

ACKNOWLEDGEMENTS
This work is supported by funds from the Natural Science and Engineering Research Council of Canada and from the Faculty of Health, York University. GM is a recipient of Ontario Graduate Scholarship.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
GM and OAJA conceived and designed the experiments. GM performed the experiments and drafted the initial version of the manuscript. OAJA reviewed and edited the manuscript. Both authors approved the final version of the manuscript.

ORCID
Olasunkanmi A. J. Adegoke https://orcid.org/0000-0002-9697-9318

REFERENCES
Adams, S. H. (2011). Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Advances in Nutrition, 2(6), 445–456.

Aguirre, V., Uchida, T., Yenush, L., Davis, R., & White, M. F. (2000). The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. Journal of Biological Chemistry, 275(12), 9047–9054.

Andersson-Hall, U., Gustavsson, C., Pedersen, A., Malmadin, D., Joelsson, L., & Holmäng, A. (2018). Higher concentrations of BCAAs and 3-HIB are associated with insulin resistance in the transition from gestational diabetes to type 2 diabetes. Journal of Diabetes Research 2018, https://doi.org/10.1155/2018/4207067

Baum, J. I., O’Connor, J. C., Seyler, J. E., Anthony, T. G., Freund, G. G., & Layman, D. K. (2005). Leucine reduces the duration of insulin-induced PI 3-kinase activity in rat skeletal muscle. American Journal of Physiology – Endocrinology and Metabolism, 288(1):86–91.

Beg, M., Abdullah, N., Thowfeik, F. S., Altorki, N. K., & McGraw, T. E. (2017). Distinct Akt phosphorylation states are required for insulin-induced PI 3-kinase signaling in rat skeletal muscle. Cell Metabolism, 21(5), 884–896.

Bhatnagar, S., Panguluri, S. K., Gupta, S. K., Dahiya, S., Lundy, R. F., & Kumar, A. (2010). Tumor necrosis factor-α regulates distinct molecular pathways and gene networks in cultured skeletal muscle cells. PLoS One, 5(10), e13262

Binder, E., Bermúdez-Silva, F. J., André, C., Elie, M., Romero-Zerbo, S. Y., Leste-Lasserre, T., Belluomollaria, L., Duchampt, A., Clark, S., Aubert, A., Mezzullo, M., Fanelli, F., Pagotto, U., Layé, S., Mathieu, G., & Cota, D. (2013). Leucine supplementation protects from insulin resistance by regulating adiposity levels. PLoS One, 8(9), e74705

Brosnan, J. T., & Brosnan, M. E. (2006). Branched-chain amino acids: enzyme and substrate regulation. Journal of Nutrition, 136(5), 269–273.

Bunt, J. C., Krakoff, J., Ortega, E., Knowler, W. C., & Bogardus, C. (2007). Acute insulin response is an independent predictor of type 2 diabetes mellitus in individuals with both normal fasting and 2-h plasma glucose concentrations. Diabetes Metabolism Research and Reviews, 23(4), 304–310.

Ciaraldi, T. P., Carter, L., Mudaliar, S., Kern, P. A., & Henry, R. R. (1998). Effects of tumor necrosis factor-α on glucose metabolism in cultured human muscle cells from nondiabetic and type 2 diabetic subjects. Endocrinology, 139(12), 4793–4800.

Cummings, N. E., Williams, E. M., Kasza, I., Konon, E. N., Schaid, M. D., Schmidt, B. A. et al. (2018). Restoration of metabolic health by decreased consumption of branched-chain amino acids. Journal of Physiology, 596(4), 623–645.

DeFronzo, R. A., & Tripathy, D. (2009). Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care, 32(Suppl), 2.

Feinstein, R., Kanety, H., Papa, M. Z., Lunenfeld, B., & Karasik, A. (1993). Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. Journal of Biological Chemistry, 268(35), 26055–26058.

Felg, P., Marliss, E., & Cahill, G. F. (1969). Plasma amino acid levels and insulin secretion in obesity. New England Journal of Medicine, 281(15), 811–816.

Fujimoto, W. Y. (2000). The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. American Journal of Medicine, 108(6 Suppl. 1), 9–14.

Giesbertz, P., Padberg, I., Rein, D., Ecker, J., Höflé, A. S., Spanier, B. et al. (2015). Metabolite profiling in plasma and tissues of ob/ob and db/db mice identifies novel markers of obesity and type 2 diabetes. Diabetologia, 58(9), 2133–2143.

Gual, P., Le Marchand-Brustel, Y., & Tanti, J. F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie, 2005;87(1 spec. iss.):99–109.

Harper, A. E., Miller, R. H., & Block, K. P. (1984). Branched-chain amino acid metabolism. Metabolism, 33(6), 409–454.

Herman, M. A., She, P., Peroni, O. D., Lynch, C. J., & Kahn, B. B. (2010). Adipose tissue branched chain amino acid (BCAA) metabolism modulates circulating BCAA levels. Journal of Biological Chemistry, 285(15), 11348–11356.

Hernández-Alvarez, M. I., Díaz-Ramos, A., Berdasco, M., Cobb, J., Planet, E., Cooper, D. et al. (2017). Early-onset and classical forms of type 2 diabetes show impaired expression of genes involved in muscle branched-chain amino acids metabolism. Scientific Reports, 7(1), 1–12.

Hotamisligil, G., Shargill, N., & Spiegelman, B. (1993). Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance Author (s): Gökhan S. Hotamisligil, Narinder S. Shargill and Bruce M. Spiegelman Published by : American Association for the Advancement of Science Stab. Science (80-), 259(5091), 87–91.

Ishikawa, T., Kitaura, Y., Kadota, Y., Morishita, Y., Ota, M., Yamanaka, F. et al. (2016). Muscle-specific deletion of BDK amplifies loss of myofibrillar protein during protein undernutrition. Scientific Reports, 2017(7), 1–11.

Jang, C., Oh, S. F., Wada, S., Rowe, G. C., Liu, L., Chan, C. et al. (2016). A branched chain amino acid metabolite drives vascular...
transport of fat and causes insulin resistance. *Nature Medicine*, 22(4), 421–426.

Jeganathan, S., Abdullahi, A., Zargar, S., Maeda, N., Riddell, M. C., & Adegoke, O. A. J. (2014). Amino acid-induced impairment of insulin sensitivity in healthy and obese rats is reversible. *Physiol Rep*, 7(2), e12067.

Kim, J. H., Bachmann, R. A., & Chen, J. (2009). Chapter 21 interleukin-6 and insulin resistance. *Vitamins and Hormones*, 80(C), 613–633.

Kuzuya, T., Katano, Y., Nakano, I., Hirooka, Y., Itoh, A., Ishigami, M. et al. (2008). Regulation of branched-chain amino acid catabolism in rat models for spontaneous type 2 diabetes mellitus. *Biochemical and Biophysical Research Communications*, 373(1), 94–98.

Lackey, D. E., Lynch, C. J., Olson, K. C., Mostaedi, R., Ali, M., Smith, W. H. et al. (2013). Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. *American Journal of Physiology - Endocrinology Metabolism*, 304(11), E1175–1187.

Lee, S., Gulseth, H. L., Refsum, H., Langleite, T. M., Holen, T., Lackey, D. E., Lynch, C. J., Olson, K. C., Mostaedi, R., Ali, M., Smith, Kuzuya, T., Katano, Y., Nakano, I., Hirooka, Y., Itoh, A., Ishigami, M. et al. (2008). Regulation of branched-chain amino acid catabolism in rat models for spontaneous type 2 diabetes mellitus. *Biochemical and Biophysical Research Communications*, 373(1), 94–98.

Li, Y., Jiang, C., Xu, G., Wang, N., Zhu, Y., Tang, C. et al. (2008). Homocysteine upregulates resistin production from adipocytes in vivo and in vitro. *Diabetes*, 57, 817–827.

Lian, K., Du, C., Liu, Y., Zhu, D., Yan, W., Zhang, H. et al. (2015). Impaired adiponectin signaling contributes to disturbed catabolism of branched-chain amino acids in diabetic mice. *Diabetes*, 64(1), 49–59.

Lipton, S. A., Kim, W. K., Choi, Y. B., Kumar, S., D’Emilia, D. M., Rayudu, P. V. et al. (1997). Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. *Proceedings of National Academy Sciences USA*, 94(11), 5923–5928.

Lovic, D., Piperidou, A., Zografou, I., Grassos, H., Pittaras, A., & Manolis, A. (2019). The growing epidemic of diabetes mellitus. *Current Vascular Pharmacology*, 18(2), 104–109.

Lynch, C. J., & Adams, S. H. (2014). Branched-chain amino acids in metabolic signalling and insulin resistance. *Nature Reviews Endocrinology*, 10(12), 723–736.

Macotela, Y., Emanuelli, B., Bäng, A. M., Espinoza, D. O., Boucher, J., Beebe, K. et al. (2011). Dietary leucine - an environmental modifier of insulin resistance acting on multiple levels of metabolism. *PLoS One*, 6(6).

Mccormack, S. E., Shaham, O., Mccarthy, M. A., Deik, A. A., Wang, T. J., Gerszten, R. E. et al. (2013). Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. *Pediatric Obesity*, 8(1), 52–61.

Moghe, M., Tavajohi-Fini, P., Beatty, B., & Adegoke, O. A. J. (2016). Ketoisocaproic acid, a metabolite of leucine, suppresses insulin-stimulated glucose transport in skeletal muscle cells in a BCAT2-dependent manner. *American Journal of Physiology - Cell Physiology*, 311(3), C518–C527.

Newgard, C. B. (2012). Interplay between lipids and branched-chain amino acids in development of insulin resistance. *Cell Metabolism*, 15(5), 606–614.

Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F. et al. (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metabolism* [Internet], 9(4), 311–326. https://doi.org/10.1016/j.cmet.2009.02.002

Nieto-Vazquez, I., Fernandez-Feleldo, S., De Alvaro, C., & Lorenzo, M. (2008). Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. *Diabetes*, 57(12), 3211–3221.

Nishitani, S., Matsumura, T., Fujitani, S., Sonaka, I., Miura, Y., & Yagasaki, K. (2002). Leucine promotes glucose uptake in skeletal muscle of rats. *Biochemical and Biophysical Research Communications*, 299(5), 693–696.

Olokoba, A. B., Obateru, O. A., & Olokoba, L. B. (2012). Type 2 diabetes mellitus: a review of current trends. *Oman Medical Journal*, 27(4), 269–273.

Pederson, T. M., Kramer, D. L., & Rondinone, C. M. (2001). Serine/threonine phosphorylation of IRS-1 triggers its degradation: Possible regulation by tyrosine phosphorylation. *Diabetes*, 50(1), 24–31.

Pereira, S., Marliess, E. B., Morais, J. A., Chevaletier, S., & Gougeon, R. (2008). Insulin resistance of protein metabolism in type 2 diabetes and impact on dietary needs: A review. *Diabetes*, 57(1), 56–63.

Pereng, W., Gillman, M. W., Fleisch, A. F., Michalek, R. D., Watkins, S. M., Isganaitis, E. et al. (2014). Metabolic profiles and childhood obesity. *Obesity*, 22(12), 2570–2578.

Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P. et al. (1997). Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. *Immunity*, 6(3), 315–325.

She, P., Reid, T. M., Bronson, S. K., Vary, T. C., Hajnal, A., Lynch, C. J. et al. (2007). Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. *Cell*, 6(3), 181–194.

Shimomura, Y., Murakami, T., Nakai, N., Nagasaki, M., & Harris, R. A. (2004). Exercise promotes BCAA catabolism: Effects of BCAA supplementation on skeletal muscle during exercise. *Journal of Nutrition*, 134(6 Suppl.), 1583–1587.

Shimomuras, Y., Yamamoto, Y., Bajott, G., Sato, J., Murakami, T., Shimomura, N. et al. (2006). Nutraceutical effects of branched-chain amino acids on skeletal muscle. *Journal of Nutrition*, 136, 525–528.

Shoelson, S. E., Lee, J., & Goldfine, A. B. (2006). Inflammation and insulin resistance. *Journal of Clinical Investigation*, 116(0021-9738 (Print)), 1793–1801.

Singh, B., & Saxena, A. (2010). Surrogate markers of insulin resistance: A review. *World Journal of Diabetes*, 1(2), 36–47.

Somwar, R., Sweeney, G., Ramal, T., & Klip, A. (1998). Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells. *Clinical Therapeutics*, 20(1), 125–140.

Suryawan, A., Hawes, J. W., Harris, R. A., Shimomura, Y., Jenkins, A. E., & Hutson, S. M. (1998). A molecular model of human branched-chain amino acid metabolism. *American Journal of Clinical Nutrition*, 68(1), 72–81.

Thiebaud, D., Jacot, E., DeFronzo, R. A., Maeder, E., Jequier, E., & Hutson, S. M. (1998). A molecular model of human branched-chain amino acid metabolism. *American Journal of Clinical Nutrition*, 68(1), 72–81.

Tremlay, F., & Marette, A. (2001). Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback
mechanism leading to insulin resistance in skeletal muscle cells. *Journal of Biological Chemistry*, 276(41), 38052–38060.

Um, S. H., D’Alessio, D., & Thomas, G. (2006). Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. *Cell Metabolism*, 3(6), 393–402.

Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M. et al. (2004). Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature*, 431(7005), 200–205.

Unnikrishnan, R., Pradeepa, R., Joshi, S. R., & Mohan, V. (2017). Type 2 diabetes: Demystifying the global epidemic. *Diabetes*, 66(6), 1432–1442.

ViM, P., & Garlick, P. J. (1975). Effect of streptozotocin diabetes and insulin treatment on the rate of protein synthesis in tissues of the rat in vivo. *Journal of Biological Chemistry*, 414(1), 71–84.

Wagenmakers, A. J. M., Brookes, J. H., Coakley, J. H., Reilly, T., & Edwards, R. H. T. (1989). Exercise-induced activation of the branched-chain 2-oxo acid dehydrogenase in human muscle. *European Journal of Applied Physiology and Occupational Physiology*, 59, 159–167.

Wang, G., Siow, Y. L., & O, K. (2000). Homocysteine stimulates nuclear factor κB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: A possible role for protein kinase C. *The Biochemical Journal*, 352(3), 817–825.

Wang, G., Woo, C. W. H., Sung, F. L., Siow, Y. L., & Karmin, O. (2002). Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: Role of chemokine and adhesion molecules. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 22(11), 1777–1783.

Zargar, S., Moreira, T. S., Samimi-Seisan, H., Jeganathan, S., Kakade, D., Islam, N. et al. (2011). Skeletal muscle protein synthesis and the abundance of the mRNA translation initiation repressor PDCD4 are inversely regulated by fasting and refeeding in rats. *American Journal of Physiology - Endocrinology Metabolism*. https://doi.org/10.1152/ajpendo.00642.2010

Zhou, M., Shao, J., Wu, C. Y., Shu, L., Dong, W., Liu, Y. et al. (2019). Targeting BCAA catabolism to treat obesity-associated insulin resistance. *Diabetes*, 68(9), 1730–1746.

Zhou, Y., Jetton, T. L., Goshorn, S., Lynch, C. J., & She, P. (2010). Transamination is required for α-ketoisocaproate but not leucine to stimulate insulin secretion. *Journal of Biological Chemistry*, 285(44), 33718–33726.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Mann G, Adegoke OA. Effects of ketoisocaproic acid and inflammation on glucose transport in muscle cells. *Physiol Rep*. 2021;9:e14673. [https://doi.org/10.14814/phy2.14673](https://doi.org/10.14814/phy2.14673)